InvestorsObserver
×
News Home

Should You Sell ORIC Pharmaceuticals Inc (ORIC) in Biotechnology Industry?

Wednesday, December 28, 2022 10:06 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Sell ORIC Pharmaceuticals Inc (ORIC) in Biotechnology Industry?

ORIC Pharmaceuticals Inc (ORIC) is near the top in its industry group according to InvestorsObserver. ORIC gets an overall rating of 62. That means it scores higher than 62 percent of stocks. ORIC Pharmaceuticals Inc gets a 76 rank in the Biotechnology industry. Biotechnology is number 57 out of 148 industries.

Overall Score - 62
ORIC has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on ORIC!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With ORIC Pharmaceuticals Inc Stock Today?

ORIC Pharmaceuticals Inc (ORIC) stock is trading at $5.71 as of 9:50 AM on Wednesday, Dec 28, a gain of $0.26, or 4.77% from the previous closing price of $5.45. The stock has traded between $5.38 and $5.85 so far today. Volume today is light. So far 84,250 shares have traded compared to average volume of 1,644,946 shares. Click Here to get the full Stock Report for ORIC Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App